Typed states for the displayed outbound observations.
Source: paper_references, paper_reference_links, observed 2026-08-10T20:22:00.646949Z
Paper Citation Record · LEDGER
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab
As of 12 August 2026, this Paper Citation Record lists 81 of 81 outbound references and 0 inbound Pith citation observations for arXiv:2501.08744.
A citation records a reference. It does not transfer a finding from one paper to another.
Coverage vector
One-hop event checks from named stored sources.
Source: scholarly_work_events, retraction_status_cache, observed 2026-08-12T06:34:41.77262+00:00
Pith citing papers itemized under the disclosed page cap.
Source: paper_references, paper_reference_links
A source-named dated measurement, never combined with another source.
Source: cited_works
Reference resolution
81 of 81 outbound references displayed
- verified exact62
- verified fuzzy6
- unresolved7
- parse uncertain0
- malformed identifier5
- metadata mismatch1
External citation measurements
No source-named external measurement is stored.
Outbound references
Observation d563f134-2bf1-40d2-9394-83463f20a8a6 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 1
- Resolution
- unresolved
- raw_fallback, observed 2026-08-10T20:22:01.740946Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation f224a5b4-9d3e-48fb-b748-df200357e96e · outbound
This paper cites This common/pooled RTE is assigned a vague normal prior distribution, ~ (0,1000)dN.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab This common/pooled RTE is assigned a vague normal prior distribution, ~ (0,1000)dN
Reference 2
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-10T20:22:01.729326Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation c9f65e27-d52a-4e76-ae54-148af1c0c2b4 · outbound
This paper cites The pooled parameter dm is assigned a vague normal prior distribution and a weakly informative half-normal prior distribution is assigned to the standard deviation, d.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab The pooled parameter dm is assigned a vague normal prior distribution and a weakly informative half-normal prior distribution is assigned to the standard deviation, d
Reference 3
- Resolution
- malformed identifier
- raw_fallback, observed 2026-08-10T20:22:01.717485Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation bbe61f6f-7cfa-434d-bf15-02c280f4f470 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 4
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.819844Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 506868eb-6d7f-45c1-a854-e1bf862890d9 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 5
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.809145Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 94fcd6f2-f4c6-4e27-b2cc-aca4363f8e75 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 6
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.798852Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation a54fecb0-d673-4a41-8f8f-a090da3d302a · outbound
This paper cites Biomarker results from the A V ADO phase 3 trial of first- line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Biomarker results from the A V ADO phase 3 trial of first- line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
Reference 7
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.788297Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 143ca053-4a17-4750-afc9-d03c3a850c33 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 8
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.775893Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 87451710-3c93-48e9-a476-a087dfe8620c · outbound
This paper cites Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial
Reference 9
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.764936Z
Source-reported events for the cited work
correction dated 2011-08-03. Source: crossref record 10.1016/j.clbc.2011.06.004->10.1016/j.clbc.2011.03.005:correction, observed 2026-07-11T03:12:43.466735+00:00. This notice travels one citation hop only.
Observation 9d1dd3bd-82b6-4e0d-9192-5535340d2e35 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 10
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.752191Z
Source-reported events for the cited work
correction dated 2011-08-02. Source: crossref record 10.1016/s1470-2045(11)70205-4->10.1016/s1470-2045(11)70037-7:correction, observed 2026-07-11T03:17:45.890087+00:00. This notice travels one citation hop only.
Observation 6f697f93-70e5-471f-8553-a5cf184f4d02 · outbound
This paper cites Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study
Reference 11
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.740392Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation b9496b2c-7590-4ce3-b56b-81b8fb34790e · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 12
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.727640Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation bbbc6bec-fd8f-4fd1-bd12-86f9f0c7c851 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 13
- Resolution
- unresolved
- raw_fallback, observed 2026-08-10T20:22:01.705821Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 474d4a03-f840-4833-b3eb-dd68048ef2d1 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 15
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.480166Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 465b5e09-69a4-473b-8ba3-14daaa64c38e · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 16
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.470146Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 27263ccb-c647-441d-afa1-ffb4a141c66c · outbound
This paper cites Improved survival with bevacizumab in advanced cervical cancer.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Improved survival with bevacizumab in advanced cervical cancer
Reference 17
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.458992Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 1407a4fc-3044-4d94-ab6b-aebd6342f4c8 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 18
- Resolution
- malformed identifier
- no resolver link, observed 2026-08-10T20:22:00.470736Z
Source-reported events for the cited work
Unavailable: canonical work link unavailable.
Observation 533af837-8f09-45a4-b438-976ac6f9079a · outbound
This paper cites Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
Reference 19
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.435165Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 284b8049-3ffd-4983-b9bf-6456fd30bf58 · outbound
This paper cites Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial
Reference 20
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.422927Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 80402f93-7729-4943-929d-409aa314679a · outbound
This paper cites Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Reference 21
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.411108Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation c5f8d6fa-cd0a-4845-a2d9-f3333b95ac2e · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 22
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.398942Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation fd9b26fd-c938-4242-92f6-1d928678583f · outbound
This paper cites Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
Reference 23
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.387409Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 72d62f28-fdcf-426a-bbb3-314dc3c6fc47 · outbound
This paper cites XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
Reference 24
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.376226Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation af7c4c0d-f3fa-41bf-892a-ca58036b134c · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 25
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.364431Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation d35ee039-2697-48f3-97f9-a500496bf647 · outbound
This paper cites Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
Reference 26
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.353252Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 2c14b25d-0d11-42c7-80ee-6eb35ebe0f30 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 27
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.341235Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 503a9aa2-042b-4635-a4f8-315c7c964705 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 28
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.328360Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation ce23734f-6a3a-4d04-b299-df57f6fab278 · outbound
This paper cites Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (A VEX): an open- label, randomised phase 3 trial.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (A VEX): an open- label, randomised phase 3 trial
Reference 29
- Resolution
- malformed identifier
- no resolver link, observed 2026-08-10T20:22:00.510334Z
Source-reported events for the cited work
Unavailable: canonical work link unavailable.
Observation 4436beaf-1826-46bb-ad37-16f525ee1a2e · outbound
This paper cites Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
Reference 30
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.304038Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation b29e1c59-31e5-4e6b-b151-a635a5b01bf9 · outbound
This paper cites A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab A randomized trial of bevacizumab for newly diagnosed glioblastoma
Reference 31
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.290827Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation f9a61b50-a85c-4b6b-a991-4785d12c50ac · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 32
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.279531Z
Source-reported events for the cited work
correction dated 2016-08-24. Source: crossref record 10.1200/jco.2016.69.6674->10.1200/jco.2015.61.5005:correction, observed 2026-07-11T02:56:59.531935+00:00. This notice travels one citation hop only.
Observation 25f584ae-1d8f-4b3e-b1f3-5b769a6ca016 · outbound
This paper cites EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma
Reference 33
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.267282Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 63fe323d-f90a-46c5-bbee-e3a5af8d7ff5 · outbound
This paper cites Paclitaxel-carboplatin alone or with bevacizumab for non- small-cell lung cancer.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Paclitaxel-carboplatin alone or with bevacizumab for non- small-cell lung cancer
Reference 34
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.255140Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 93b97b06-da19-4836-9341-25c4c268ce99 · outbound
This paper cites Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: A V Ail.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: A V Ail
Reference 35
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.241749Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation b8f00e9e-18d2-4c3f-bcb3-bb928ff2e6ab · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 36
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.229113Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation f540eeca-2a6b-4cc6-b7fd-11ee4932a229 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 37
- Resolution
- unresolved
- raw_fallback, observed 2026-08-10T20:22:01.694912Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 2926a412-04ab-4879-a995-4edd77895682 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 38
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.203106Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 774cf3c2-e4d8-47d6-bac6-45bbeee8a6c3 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 39
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.187316Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 73b713b3-4080-4e17-adbe-57867d61ffba · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 40
- Resolution
- unresolved
- raw_fallback, observed 2026-08-10T20:22:01.683931Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation ffb3556a-8fe8-42e7-8034-bfe68b561cb5 · outbound
This paper cites IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Reference 41
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.163658Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 80f9434f-ab1e-4159-8f28-a3783ce6be75 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 42
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.138049Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation e5ab4c71-72ac-4a72-8229-1bece14f149a · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 43
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.695676Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation ef0672ab-8495-461f-adc8-c136e06276e0 · outbound
This paper cites Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Incorporation of bevacizumab in the primary treatment of ovarian cancer
Reference 44
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.107182Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation a0ff79dc-c504-4599-8309-9d105b722830 · outbound
This paper cites Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Reference 45
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.090622Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation beb30c89-3aec-46f7-b928-c0739a6fccec · outbound
This paper cites A phase 3 trial of bevacizumab in ovarian cancer.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab A phase 3 trial of bevacizumab in ovarian cancer
Reference 46
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.077249Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 33fdf2ed-9e25-4640-8fa7-5ecc9119333f · outbound
This paper cites Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial
Reference 47
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.056962Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 616b779f-11da-44c7-9eec-f9f141a740a4 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 48
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.043126Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 2fe6f5c1-7d67-43c8-9f06-35d13417f996 · outbound
This paper cites Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Reference 49
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.029087Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 5d682c8c-2b78-4e9e-a0f7-6fba75ffd206 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 50
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.682714Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation eeedaa85-d612-4ac4-a05e-4883d1678511 · outbound
This paper cites Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
Reference 51
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.009857Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 40d45e4e-65b4-4903-96f4-d292fa73c85c · outbound
This paper cites Bevacizumab with or after chemotherapy for platinum- resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab with or after chemotherapy for platinum- resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
Reference 52
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.998021Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation afc67627-1073-45a6-980b-ed0a984e9212 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 53
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.986892Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 99c06af9-c50d-4fe4-b96a-461b67d8c5fe · outbound
This paper cites A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
Reference 54
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.975600Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 4155ebfc-98c7-49d2-88f3-efaf3b2552f9 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 55
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.491748Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 98904ff8-be65-4106-9cab-a44af26949c0 · outbound
This paper cites Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Reference 59
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.447499Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 873f2042-e766-4a01-94ad-d376fc5d8c72 · outbound
This paper cites Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Reference 62
- Resolution
- unresolved
- no resolver link, observed 2026-08-10T20:22:00.202876Z
Source-reported events for the cited work
Unavailable: canonical work link unavailable.
Observation 3988e2f6-8d43-4544-ab6b-865cc525d2de · outbound
This paper cites Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (A VEX): an open-label, randomised phase 3 trial.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (A VEX): an open-label, randomised phase 3 trial
Reference 70
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.316275Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 6155dce0-8e60-4668-9e94-4a399fe45688 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 73
- Resolution
- unresolved
- raw_fallback, observed 2026-08-10T20:22:01.773693Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 409297a9-ee90-49c3-a43a-9435ddd42f80 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 81
- Resolution
- malformed identifier
- no resolver link, observed 2026-08-10T20:22:00.289765Z
Source-reported events for the cited work
Unavailable: canonical work link unavailable.
Observation 1fe2a228-e35e-48a7-a1b6-228b852bcee0 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 84
- Resolution
- malformed identifier
- doi_truncated, observed 2026-08-10T20:22:01.122158Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation a3b6001f-9cb2-4c88-889c-c53a7b012590 · outbound
This paper cites Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced 30 Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced 30 Urothelial Carcinoma: Results of CALGB 90601 (Alliance)
Reference 103
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-10T20:22:01.763297Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation e085776d-211b-479e-9a2b-7b079a9ecc99 · outbound
This paper cites On weakly informative prior distributions for the heterogeneity parameter in Bayesian random‐effects meta‐analysis.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab On weakly informative prior distributions for the heterogeneity parameter in Bayesian random‐effects meta‐analysis
Reference 106
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-10T20:22:01.751966Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 82774529-ebd5-4a9a-a670-533aef9986c1 · outbound
This paper cites Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
Reference 107
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.856845Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 8dd591cd-be97-4c42-9f78-465907be9623 · outbound
This paper cites Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Reference 108
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.844662Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 8606b344-9d2c-432e-bbc5-1b99b083846a · outbound
This paper cites Bevacizumab in the first-line treatment of metastatic breast cancer.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab in the first-line treatment of metastatic breast cancer
Reference 109
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.831065Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 0eb3da54-2e89-46f4-87d8-989b83003e47 · outbound
This paper cites Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
Reference 115
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.963962Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 34ec7524-e127-4126-a769-4aa6643018b3 · outbound
This paper cites Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
Reference 116
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.951885Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation c609bc6f-6896-4855-8fd0-83b61b23c008 · outbound
This paper cites Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Reference 117
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-10T20:22:01.672546Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 17a47edf-fe0c-4c2c-9eed-69517b6d054a · outbound
This paper cites Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (A VOREN): final analysis of overall survival.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (A VOREN): final analysis of overall survival
Reference 119
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.927619Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation fb0f8d45-6448-4fa3-8ed4-ab5c18d1fbe6 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 120
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.916610Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 006bf548-801e-472d-ae2d-cfbb48b0664f · outbound
This paper cites Bevacizumab in combination with chemotherapy as first- line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab in combination with chemotherapy as first- line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study
Reference 121
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.905920Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation f7bf03a2-2a2e-4af2-86bc-b98ae90bef06 · outbound
This paper cites R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: Final MAIN study outcomes.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: Final MAIN study outcomes
Reference 122
- Resolution
- metadata mismatch
- raw_fallback, observed 2026-08-10T20:22:01.618955Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 9e59c117-db0b-4037-8d00-0b0f55ad0109 · outbound
This paper cites Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)
Reference 123
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.892970Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation f7facc4d-9b14-44cc-8534-00e3fca312dc · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 124
- Resolution
- unresolved
- raw_fallback, observed 2026-08-10T20:22:01.660315Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 711aa054-97f6-4458-9545-26827acdc170 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 126
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.867601Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 49b953c8-be43-4a58-99dc-37a67a51182d · outbound
This paper cites Bayesian methods in meta-analysis and evidence synthesis.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bayesian methods in meta-analysis and evidence synthesis
Reference 127
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-10T20:22:01.648786Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation f9d59e0e-422f-40cf-95d3-3da100260b59 · outbound
This paper cites On weakly informative prior distributions for the heterogeneity parameter in Bayesian random‐effects meta‐analysis.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab On weakly informative prior distributions for the heterogeneity parameter in Bayesian random‐effects meta‐analysis
Reference 128
- Resolution
- verified fuzzy
- raw_fallback, observed 2026-08-10T20:22:01.633009Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 69fe44ee-0d37-4f82-b583-06018e308e5b · outbound
This paper cites DOI: 10.1016/s2213-2600(19)30084-0.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab DOI: 10.1016/s2213-2600(19)30084-0
Reference 401
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.708404Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation 373f3541-b6fb-4c7c-b492-59b2811c888f · outbound
This paper cites DOI: 10.1016/s1470-2045(14)70381-x.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab DOI: 10.1016/s1470-2045(14)70381-x
Reference 1244
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:01.216069Z
Source-reported events for the cited work
correction dated 2014-09-30. Source: crossref record 10.1016/s1470-2045(14)70506-6->10.1016/s1470-2045(14)70381-x:correction, observed 2026-07-11T03:14:07.972603+00:00. This notice travels one citation hop only.
Observation 3dba0e75-b4f3-4c49-a927-1623ca5480b0 · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 1540
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.879637Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Observation bd52ef17-eb81-4ae2-aee2-23ffe933c46e · outbound
This paper cites an unresolved cited work.
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work
Reference 2111
- Resolution
- verified exact
- doi, observed 2026-08-10T20:22:00.939515Z
Source-reported events for the cited work
No event found in the named queried sources as of 2026-08-12T06:34:41.77262+00:00.
Pith citing papers
No inbound Pith citation observations are available.